Monitoring measurable residual disease in NUP98::NSD1-positive acute myeloid leukemia.

IF 1 4区医学 Q3 PEDIATRICS

Pediatrics International Pub Date : 2025-01-01 DOI:10.1111/ped.15859

Ikuo Okuchi, Akira Nishimura, Takahiro Kamiya, Makiko Sasaki, Motoi Yamashita, Akihiro Hoshino, Michiko Kajiwara, Takeshi Isoda, Hirokazu Kanegane, Tomohiro Morio, Masatoshi Takagi

{"title":"Monitoring measurable residual disease in NUP98::NSD1-positive acute myeloid leukemia.","authors":"Ikuo Okuchi, Akira Nishimura, Takahiro Kamiya, Makiko Sasaki, Motoi Yamashita, Akihiro Hoshino, Michiko Kajiwara, Takeshi Isoda, Hirokazu Kanegane, Tomohiro Morio, Masatoshi Takagi","doi":"10.1111/ped.15859","DOIUrl":null,"url":null,"abstract":"Background: NUP98 fusion genes are detected in acute myeloid leukemia (AML) subgroups that have a poor prognosis. An appropriate therapeutic approach should therefore be established. Treatment intensification according to the minimal residual disease (MRD) level can lead to a better prognosis in patients with acute lymphoblastic leukemia (ALL). However, the importance of MRD monitoring in the patient with NUP98-positive AML is unclear.Methods: This study aimed to develop a digital droplet polymerase chain reaction (ddPCR) method for monitoring NUP98::NSD1-positive leukemic cells and to report its utility compared with the results of NUP98 split fluorescence in situ hybridization (FISH).Results: The results of NUP98::NSD1 ddPCR correlated with those of NUP98 split FISH and were more sensitive than NUP98 split FISH. The sensitivity of ddPCR was 0.001%, equivalent to 1 in 1 × 105 cells. The MRD level of NUP98::NSD1, measured by ddPCR, correlated well with relapse.Conclusion: The use of ddPCR to target NUP98::NSD1 chimera mRNA for MRD monitoring would be beneficial for NUP98::NSD1 AML treatment.","PeriodicalId":20039,"journal":{"name":"Pediatrics International","volume":"67 1","pages":"e15859"},"PeriodicalIF":1.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatrics International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ped.15859","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: NUP98 fusion genes are detected in acute myeloid leukemia (AML) subgroups that have a poor prognosis. An appropriate therapeutic approach should therefore be established. Treatment intensification according to the minimal residual disease (MRD) level can lead to a better prognosis in patients with acute lymphoblastic leukemia (ALL). However, the importance of MRD monitoring in the patient with NUP98-positive AML is unclear.

Methods: This study aimed to develop a digital droplet polymerase chain reaction (ddPCR) method for monitoring NUP98::NSD1-positive leukemic cells and to report its utility compared with the results of NUP98 split fluorescence in situ hybridization (FISH).

Results: The results of NUP98::NSD1 ddPCR correlated with those of NUP98 split FISH and were more sensitive than NUP98 split FISH. The sensitivity of ddPCR was 0.001%, equivalent to 1 in 1 × 10⁵ cells. The MRD level of NUP98::NSD1, measured by ddPCR, correlated well with relapse.

Conclusion: The use of ddPCR to target NUP98::NSD1 chimera mRNA for MRD monitoring would be beneficial for NUP98::NSD1 AML treatment.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatrics International 医学-小儿科

CiteScore

2.00

自引率

7.10%

发文量

519

审稿时长

12 months

期刊介绍： Publishing articles of scientific excellence in pediatrics and child health delivery, Pediatrics International aims to encourage those involved in the research, practice and delivery of child health to share their experiences, ideas and achievements. Formerly Acta Paediatrica Japonica, the change in name in 1999 to Pediatrics International, reflects the Journal''s international status both in readership and contributions (approximately 45% of articles published are from non-Japanese authors). The Editors continue their strong commitment to the sharing of scientific information for the benefit of children everywhere. Pediatrics International opens the door to all authors throughout the world. Manuscripts are judged by two experts solely upon the basis of their contribution of original data, original ideas and their presentation.